BZW2: A Potential Drug Target for Many Diseases (G28969)

Target Name: BZW2

NCBI ID: G28969

BZW2

BZW2: A Potential Drug Target for Many Diseases

BZW2 (MST017) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the BZW2 family of proteins, which are known for their role in intracellular signaling. In particular, BZW2 is involved in the regulation of cell adhesion, and is thought to play a key role in the development and maintenance of tissues that are highly adhesive, such as the brain.

Recent studies have suggested that BZW2 may be a drug target (or biomarker) for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because BZW2 is involved in the regulation of many important cellular processes, and its dysfunction has been implicated in the development of these diseases.

One of the key reasons for the potential drug-targeting properties of BZW2 is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs, and is critical for the development and maintenance of these structures. BZW2 is thought to be involved in the regulation of cell adhesion by controlling the activity of adhesion molecules, which are proteins that help cells stick together.

In addition to its role in cell adhesion, BZW2 is also involved in the regulation of many other cellular processes. For example, it is thought to be involved in the regulation of cell growth, differentiation, and survival. It is also involved in the regulation of inflammation, and has been shown to play a key role in the development of various inflammatory diseases.

The dysfunction of BZW2 has been implicated in the development of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that BZW2 is often expressed at higher levels in tissues of cancer animals, and that its dysfunction is associated with the development of cancer. Similarly, BZW2 has been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and in the regulation of the immune system, which is often impaired in these diseases.

In conclusion, BZW2 is a protein that is involved in many important cellular processes and is thought to play a key role in the development and maintenance of tissues that are highly adhesive, such as the brain. Its dysfunction has been implicated in the development of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, BZW2 may be a promising drug target (or biomarker) for the development of new treatments for these diseases.

Protein Name: Basic Leucine Zipper And W2 Domains 2

Functions: Translation initiation regulator which represses non-AUG initiated translation and repeat-associated non-AUG (RAN) initiated translation by acting as a competitive inhibitor of eukaryotic translation initiation factor 5 (EIF5) function (PubMed:21745818, PubMed:28981728, PubMed:34260931, PubMed:29470543). Increases the accuracy of translation initiation by impeding EIF5-dependent translation from non-AUG codons by competing with it for interaction with EIF2S2 within the 43S pre-initiation complex (PIC) in an EIF3C-binding dependent manner (PubMed:21745818, PubMed:28981728, PubMed:34260931)

The "BZW2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BZW2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets